| Deal value | $3.9B |
|---|---|
| Share of market cap | 1853.0% |
Key highlights
- Equity value fixed at $3.9 billion based on a $3.8 billion enterprise value
- Consolidation factor set at 4.16 for ProLogium's recapitalization
- Share consolidation mechanics replaced with a direct share exchange at closing
- Aggregate company shares fixed at 93,682,924 for valuation purposes
- Target company ProLogium specializes in high-density solid-state battery technology
What Is the Deal?
Translational Development Acquisition Corp., a NASDAQ-listed special purpose acquisition company, has entered into a material amendment to its existing merger agreement with ProLogium Holding Inc. This first amendment to the Agreement and Plan of Merger establishes a fixed equity value for the transaction at $3.9 billion. This valuation is derived from a $3.8 billion enterprise value combined with $100 million in agreed net cash. The transaction aims to bring ProLogium, a prominent developer of next-generation solid-state battery technology, to the public markets through a business combination, providing the target company with a platform for continued industrial expansion.
Deal Structure & Terms
- The amendment defines a consolidation factor of 4.16 for ProLogium's recapitalization process
- Aggregate company shares are fixed at 93,682,924 to determine per-share equity value
- Former share consolidation mechanics are replaced with a share exchange immediately prior to the first merger
- The share count includes 21.8 million common shares and 67.6 million preferred shares pre-recapitalization
- ProLogium will create additional authorized shares as specified in its revised Listing Articles
Business Overview
ProLogium Holding Inc. operates as a global leader in the development and manufacturing of solid-state batteries, primarily targeting the electric vehicle sector. Unlike traditional lithium-ion batteries that utilize liquid electrolytes, ProLogium’s technology employs ceramic electrolytes, which offer significantly higher energy density and improved safety profiles by reducing the risk of thermal runaway. The company has focused on large-scale commercialization, positioning itself as a key supplier for automotive manufacturers seeking to extend vehicle range and reduce charging times for next-generation transportation solutions. This deal provides the capital necessary to scale its production facilities.
Financial Context
The $3.9 billion equity valuation represents a significant scale-up compared to TDAC’s current market capitalization of approximately $210.5 million. As a shell company, TDAC’s primary asset is its trust account intended for this business combination. The amended agreement ensures that the recapitalization mechanics align with the final $3.8 billion enterprise value, providing clarity on the ownership structure post-merger. Market interest in the vehicle remains steady, with TDAC shares trading at $10.90 and showing a relative strength index of 60.3, reflecting a stable technical position as the parties move toward the final stages of the merger process.
Up 0.2% since our story on 20 Nov: $10.90 when we broke it → $10.92 at the close on 20 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 21 Oct | $10.82 |
|---|---|
| 22 Oct | $10.81 |
| 23 Oct | $10.81 |
| 26 Oct | $10.85 |
| 27 Oct | $10.84 |
| 28 Oct | $10.85 |
| 29 Oct | $10.85 |
| 30 Oct | $10.82 |
| 2 Nov | $10.83 |
| 3 Nov | $10.86 |
| 4 Nov | $10.91 |
| 5 Nov | $10.86 |
| 6 Nov | $10.87 |
| 9 Nov | $10.87 |
| 10 Nov | $10.88 |
| 11 Nov | $10.88 |
| 12 Nov | $10.88 |
| 13 Nov | $10.88 |
| 16 Nov | $10.86 |
| 17 Nov | $10.87 |
| 18 Nov | $10.88 |
| 19 Nov | $10.90 |
| 20 Nov | $10.92 |
| Share price | $10.90 |
|---|---|
| Market cap | $210M |
| 1-month price change | +0.65% |
| Sector | Financial ServicesShell Companies |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Translational Development Acquisition Corp. announcing an amendment to its merger agreement with ProLogium Holding Inc.
Track Translational Development Acquisition Corp. live
Get the next Translational Development Acquisition Corp. SEC filing seconds after it lands.



